Autoimmune mechanisms underlying dilated cardiomyopathy.

Area of Science:

• Cardiology
• Immunology
• Pathophysiology

Background:

• Dilated cardiomyopathy (DCM) is linked to autoimmune issues, viral infections, and genetic factors.
• While cell-mediated immunity is implicated in myocarditis-induced cardiomyopathy, antimyocardial antibodies are prevalent in DCM patients.
• Previously considered epiphenomena, some autoantibodies are now recognized as directly contributing to DCM's pathophysiology.

Purpose of the Study:

• To explore the role of specific autoantibodies in the development and progression of dilated cardiomyopathy.
• To investigate the link between autoantibodies targeting cardiac receptors and ion channels and clinical manifestations like arrhythmias and heart failure.
• To evaluate the therapeutic potential of immunoadsorption for removing pathogenic autoantibodies in DCM.

Main Methods:

• Detection and characterization of various antimyocardial antibodies in DCM patient serum.
• Investigating the functional effects of specific autoantibodies, such as those targeting beta1-adrenergic receptors, muscarinic M2 receptors, Na-K-ATPase, and troponin I.
• Application of immunoadsorption therapy to remove autoantibodies in patients with refractory heart failure due to DCM.

Main Results:

• Autoantibodies targeting the beta1-adrenergic receptor are associated with persistent myocardial damage and ventricular arrhythmias in DCM.
• Antibodies against the muscarinic M2 receptor correlate with atrial fibrillation.
• Antibodies targeting Na-K-ATPase are linked to sudden cardiac death, and anti-troponin I antibodies affect calcium currents and myocardial damage.

Conclusions:

• Specific autoantibodies play a direct role in the pathophysiology of dilated cardiomyopathy, contributing to myocardial damage and arrhythmias.
• The identification of these pathogenic autoantibodies supports targeted therapeutic strategies.
• Immunoadsorption therapy offers a potential treatment for refractory heart failure in DCM patients by removing harmful autoantibodies.